VYGR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 112842 min ago

@ $7.28

Išleistas: 14 vas. 2024 @ 16:30

Grąža: 17.17%

Ankstesnis signalas: vas. 13 - 16:30

Ankstesnis signalas: Pirkimas

Grąža: -1.38 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	428 588
Vidutinė apimtis	662 596
Rinkos kapitalizacija	463.18M
EPS	$0 ( 2024-02-28 )
Kita pelno data	( $-0.440 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	2.87
ATR14	$0.0120 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Ferguson Toby	Buy	105 000	Common Stock
2024-04-02	Swartz Robin	Sell	1 357	Common Stock
2024-04-02	Sandrock Alfred	Sell	12 115	Common Stock
2024-03-25	Ferguson Toby	Buy	210 000	Stock Option (Right to Buy)
2024-03-25	Ferguson Toby	Buy	0

INSIDER POWER
44.53
Last 94 transactions
Buy: 7 546 876 \| Sell: 3 757 926

Tūris Koreliacija

Ilgas: 0.09 (neutral)

Trumpas: 0.18 (neutral)

Signal:(60.504) Neutral

Voyager Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
DYNT	0.929
DGLY	0.909
CRNC	0.909
ATNX	0.905
GFAI	0.905
LIVE	0.897
FTFT	0.896
ECOR	0.896
CFRX	0.889
APRE	0.886

10 Labiausiai neigiamai susiję koreliacijos
MTEX	-0.862
ZENV	-0.859
VERA	-0.852
GRIN	-0.848
GRPH	-0.843
DSPC	-0.835
JAN	-0.832
RIVN	-0.831
LAWS	-0.827
VERX	-0.826

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Voyager Therapeutics Inc Koreliacija - Valiuta/Žaliavos

-0.13
( neutral )

-0.32
( neutral )

0.00
( neutral )

-0.24
( neutral )

0.25
( neutral )

-0.01
( neutral )

Voyager Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$250.01M
Bruto pelnas:	$245.57M (98.22 %)
EPS:	$3.08

FY	2023
Pajamos:	$250.01M
Bruto pelnas:	$245.57M (98.22 %)
EPS:	$3.08

FY	2022
Pajamos:	$40.91M
Bruto pelnas:	$34.72M (84.87 %)
EPS:	$-1.210

FY	2021
Pajamos:	$37.42M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.890

Financial Reports:

No articles found.

Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.